Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cleveland institutions to study CAR-T in Non-Hodgkin lymphoma

University Hospitals Cleveland Medical Center press statement

Publish date:: August 16, 2018

Key clinical point: A phase 1 trial of CAR T therapy is enrolling adult patients with NHL who have not responded to standard therapies.

Major finding: The trial site has the ability to manufacture the cells on site, saving patients time.

Study details: A phase 1 trial to evaluate safety.

Disclosures: The study will be funded by University Hospitals Seidman Cancer Center.

Read the article.

Citation:

University Hospitals Cleveland Medical Center press statement

This Week's Must Reads

IL-6, CRP are Prognostic for Checkpoint Inhibition in Melanoma,

Lichenoid Dermatitis with Mycosis Fungoides Features Linked to Checkpoint Inhibitor Therapy,

Women Underrepresented as Oncology Trial Corresponding Authors,

Professional Coaching Keeps Physicians in the Game,

CMS Plans to Give MIPS an Overhaul,

Must Reads in Aggressive Lymphomas

Bispecific CAR T-cell Therapy Yields Complete Responses in Relapsed/Refractory non-Hodgkin Lymphomas,

5F9 Plus Rituximab Take a Bite Out of Drug-Resistant NHL,

‘Encouraging’ Responses Seen With Durvalumab Plus R-CHOP in DLBCL,

Chemo-Free Regimen Looks Promising in Poor-Prognosis DLBCL,

Researchers characterize new subtype of high-grade DLBCL, 3 articles from the Journal of Clinical Oncology

Menu Close